Arcturus Therapeutics Ltd (ARCT) Given Average Rating of “Buy” by Brokerages

Shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) have earned a consensus recommendation of “Buy” from the nine analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $16.50.

A number of research analysts recently weighed in on ARCT shares. ValuEngine downgraded shares of Arcturus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Zacks Investment Research raised shares of Arcturus Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Thursday, January 3rd. Laidlaw began coverage on shares of Arcturus Therapeutics in a research note on Tuesday, February 19th. They set a “buy” rating for the company. Roth Capital reaffirmed a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, February 20th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $18.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, March 19th.

NASDAQ:ARCT traded down $0.17 during trading hours on Wednesday, hitting $7.65. The stock had a trading volume of 471 shares, compared to its average volume of 84,038. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.33 and a quick ratio of 3.33. Arcturus Therapeutics has a one year low of $4.11 and a one year high of $10.00. The company has a market cap of $82.21 million, a price-to-earnings ratio of -3.56 and a beta of 2.17.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Monday, March 18th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.41. The firm had revenue of $7.58 million during the quarter, compared to analysts’ expectations of $3.59 million. Equities research analysts expect that Arcturus Therapeutics will post -2.11 EPS for the current fiscal year.

A hedge fund recently raised its stake in Arcturus Therapeutics stock. JPMorgan Chase & Co. raised its stake in Arcturus Therapeutics Ltd (NASDAQ:ARCT) by 91.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,744 shares of the biotechnology company’s stock after purchasing an additional 8,008 shares during the period. JPMorgan Chase & Co. owned 0.16% of Arcturus Therapeutics worth $148,000 as of its most recent SEC filing. 10.86% of the stock is owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

See Also: What is the NASDAQ Stock Market?

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit